Lilly's Third-Quarter Results Were Mixed; Patent Cliff Represents Major Risk
publication date: Oct 20, 2011
Lilly reported mixed third-quarter results, which revealed an earnings decline. The loss of US patent exclusivity on its top two drugs in the next couple years will be difficult to overcome. Investors may see a higher dividend yield on the stock, but only because of price declines.
This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!